MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'Archives of Drug Information' source. Wed, 17 Mar 2010 14:16:56 +0100 http://www.medworm.com/index.php?rid=3206080&cid=s_37711_13_f&fid=37711&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1753-5174.2009.00028.x Objective. To evaluate the safety, tolerability, and efficacy of ritonavir-boosted saquinavir 1000/100 mg twice daily administered as a 500 mg film-coated tablet in HIV-1-infected patients.Methods. In this open-label, observational, 24-week survey conducted in 8 European countries, eligible HIV-infected participants had been prescribed saquinavir/ritonavir in combination with other nonprotease inhibitor (PI) antiretroviral agents as part of their HIV treatment regimen. The safety (grade 3 or 4 adverse events [AEs]), tolerability (by an investigator-reported subjective rating system), and efficacy (the percentage of participants with (Source: Archives of Drug Information) Archives of Drug Information journals http://www.medworm.com/rss/comments.php?id=3206080 Tue, 26 Jan 2010 00:00:00 +0100 3206080 http://www.medworm.com/index.php?rid=3090695&cid=s_37711_13_f&fid=37711&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1753-5174.2009.00027.x Introduction. 4-Aminopyridine (fampridine), a potassium channel blocker, has demonstrated efficacy in improving lower extremity strength and walking speed in patients with multiple sclerosis. Since in vitro electrophysiologic studies are recommended for evaluating a drug's potential to prolong the QT interval and induce such cardiac arrhythmias as Torsades de Pointes, we examined the electrophysiologic effects of 4-aminopyridine (0.5, 5.0, 50, and 500 µM) on isolated canine Purkinje fibers.Methods. Microelectrodes monitored the resting membrane potential, overshoot, amplitude of action potential (AP), and maximal rate of depolarization of the AP upstroke in Purkinje fibers stimulated at 0.5 and 1.0 Hz.Results. None of the above variables were altered in the presence of 4-aminopyridine. Th... Archives of Drug Information journals http://www.medworm.com/rss/comments.php?id=3090695 Wed, 16 Dec 2009 00:00:00 +0100 3090695 http://www.medworm.com/index.php?rid=3058136&cid=s_37711_13_f&fid=37711&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1753-5174.2009.00026.x Conclusions. Efalizumab provided effective control of psoriasis in the majority of patients during the initial treatment period. The high response rates were maintained in initial responders when treatment was continued beyond 12 weeks. (Source: Archives of Drug Information) Archives of Drug Information journals http://www.medworm.com/rss/comments.php?id=3058136 Sat, 05 Dec 2009 00:00:00 +0100 3058136 http://www.medworm.com/index.php?rid=3045987&cid=s_37711_13_f&fid=37711&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1753-5174.2009.00025.x Conclusions. This open-label, uncontrolled study provides supportive evidence of the potential of efalizumab as a treatment for nail, scalp and palmoplantar psoriasis. (Source: Archives of Drug Information) Archives of Drug Information journals http://www.medworm.com/rss/comments.php?id=3045987 Wed, 02 Dec 2009 00:00:00 +0100 3045987 http://www.medworm.com/index.php?rid=3024106&cid=s_37711_13_f&fid=37711&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1753-5174.2009.00024.x Conclusions. Efalizumab demonstrated sustained control of psoriasis up to 24 weeks in patients from Latin America, confirming results seen in Phase III studies conducted in North America and Europe. (Source: Archives of Drug Information) Archives of Drug Information journals http://www.medworm.com/rss/comments.php?id=3024106 Wed, 25 Nov 2009 00:00:00 +0100 3024106 http://www.medworm.com/index.php?rid=3013978&cid=s_37711_13_f&fid=37711&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1753-5174.2009.00023.x This post-approval, open-label trial (n = 1266) assessed the efficacy of efalizumab, administered in accordance with the European label at that time, in patients with concomitant nail, scalp or palmoplantar psoriasis. Patients received subcutaneous efalizumab 1.0 mg/kg weekly for up to 20 weeks. By Week 12, an improvement from baseline of 50% or more was observed in 21.4% (181/844) of patients with nail psoriasis, 62.4% (718/1150) of patients with scalp psoriasis, and 51.4% (127/247) of patients with palmoplantar psoriasis. Quality of life improved throughout the trial, with a 50% median improvement in DLQI score after 12 weeks of treatment. Efalizumab showed promising efficacy in the treatment of nail, scalp and palmoplantar psoriasis, which was reflected in improvements in quality of lif... Archives of Drug Information journals http://www.medworm.com/rss/comments.php?id=3013978 Sat, 21 Nov 2009 00:00:00 +0100 3013978 http://www.medworm.com/index.php?rid=2960847&cid=s_37711_13_f&fid=37711&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1753-5174.2009.00022.x Conclusions. These suggest that AA may enhance the cytotoxicity of As2O3, suggesting a possible future role of AA/As2O3 combination therapy in patients with APL. (Source: Archives of Drug Information) Archives of Drug Information journals http://www.medworm.com/rss/comments.php?id=2960847 Thu, 05 Nov 2009 00:00:00 +0100 2960847 http://www.medworm.com/index.php?rid=2735684&cid=s_37711_13_f&fid=37711&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1753-5174.2009.00021.x Discussion. We observed concentration-dependent inhibition of hERG current with 4-aminopyridine doses between 0.3 and 30 mM. The concentration of 3.8 mM resulting in 50% inhibition (IC50) is approximately three orders of magnitude higher than expected therapeutic plasma concentrations, suggesting 4-aminopyridine has low potential for prolonging QT interval or inducing TdP. (Source: Archives of Drug Information) Archives of Drug Information journals http://www.medworm.com/rss/comments.php?id=2735684 Wed, 26 Aug 2009 23:00:00 +0100 2735684 http://www.medworm.com/index.php?rid=2617975&cid=s_37711_13_f&fid=37711&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1753-5174.2009.00020.x Conclusion. The expression of several genes not previously identified as part of the adrenergic signaling pathway changed in response to a single oral dose of atenolol. Variation in these genes could contribute to unexplained differences in response to [beta]-blockers. (Source: Archives of Drug Information) Archives of Drug Information journals http://www.medworm.com/rss/comments.php?id=2617975 Mon, 20 Jul 2009 23:00:00 +0100 2617975 http://www.medworm.com/index.php?rid=2407465&cid=s_37711_13_f&fid=37711&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1753-5174.2009.00019.x Conclusions. In a cross-sectional setting drugs used to treat RA did not have major adverse effects on cardiovascular risk factors and use of antimalarials was associated with beneficial lipid profiles. (Source: Archives of Drug Information) Archives of Drug Information journals http://www.medworm.com/rss/comments.php?id=2407465 Fri, 15 May 2009 04:00:00 +0100 2407465 http://www.medworm.com/index.php?rid=2407466&cid=s_37711_13_f&fid=37711&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1753-5174.2008.00015.x Conclusions. BIAsp 30 treatment in a clinical setting improved glycaemic control in type 2 diabetes patients failing OADs. (Source: Archives of Drug Information) Archives of Drug Information journals http://www.medworm.com/rss/comments.php?id=2407466 Wed, 13 May 2009 04:00:00 +0100 2407466 http://www.medworm.com/index.php?rid=2269458&cid=s_37711_13_f&fid=37711&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1753-5174.2009.00018.x Conclusions. In an open-label, uncontrolled, non-randomized, observational study allergy symptoms improved significantly in subjects treated with desloratadine. (Source: Archives of Drug Information) Archives of Drug Information journals http://www.medworm.com/rss/comments.php?id=2269458 Tue, 17 Mar 2009 04:00:00 +0100 2269458 http://www.medworm.com/index.php?rid=2218064&cid=s_37711_13_f&fid=37711&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1753-5174.2009.00016.x Conclusions. The early termination of this study precluded drawing any definitive conclusions regarding the pharmacokinetics at steady state of coadministered saquinavir/ritonavir and efavirenz. (Source: Archives of Drug Information) Archives of Drug Information journals http://www.medworm.com/rss/comments.php?id=2218064 Fri, 27 Feb 2009 05:00:00 +0100 2218064 http://www.medworm.com/index.php?rid=1848520&cid=s_37711_13_f&fid=37711&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1753-5174.2008.00014.x Conclusions. Ability of UGT1A1 or baseline bilirubin to predict neutropenia is low and depends on regimen. (Source: Archives of Drug Information) Archives of Drug Information journals http://www.medworm.com/rss/comments.php?id=1848520 Fri, 03 Oct 2008 04:00:00 +0100 1848520 http://www.medworm.com/index.php?rid=1755708&cid=s_37711_13_f&fid=37711&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1753-5174.2008.00013.x Introduction. Recombinant granulocyte colony-stimulating factor (G-CSF) may aid engraftment post high-dose chemo-/radiotherapy in patients with haematological malignancies undergoing allogeneic bone marrow transplantation (BMT); however, the effects of G-CSF on graft-versus-host disease (GvHD), relapse, and survival are not well defined.Methods. In this double-blind, randomized, placebo-controlled, multicentre, phase 3 study, the effects of the G-CSF Filgrastim on neutrophil and platelet recovery, and on clinical outcomes were evaluated. Patients (12[ndash]55 years) receiving an allogeneic BMT for a haematological malignancy were randomized to receive Filgrastim 5 µg/kg or placebo. Study treatment was continued until patients achieved an absolute neutrophil count (ANC) [ge]0.5 × 109/L, o... Archives of Drug Information journals http://www.medworm.com/rss/comments.php?id=1755708 Wed, 03 Sep 2008 04:00:00 +0100 1755708 http://www.medworm.com/index.php?rid=1740082&cid=s_37711_13_f&fid=37711&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1753-5174.2008.00012.x Conclusions. A significant treatment effect was not demonstrated in this study using a treatment-withdrawal methodology. In future studies of functional dyspepsia patients with heartburn, a more rigorous parallel-group study design should be considered. (Source: Archives of Drug Information) Archives of Drug Information journals http://www.medworm.com/rss/comments.php?id=1740082 Thu, 28 Aug 2008 04:00:00 +0100 1740082 http://www.medworm.com/index.php?rid=1649756&cid=s_37711_13_f&fid=37711&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1753-5174.2008.00011.x Conclusions. These findings suggest that discussions alone do not provide patients with sufficient understanding of the events, nor do they appear to adequately equip patients to cope with them. Therefore, efforts to improve cancer care should focus on developing tools to improve patients' understanding of the toxicities of chemotherapy, as well as providing resources to reduce the effects of adverse events. (Source: Archives of Drug Information) Archives of Drug Information journals http://www.medworm.com/rss/comments.php?id=1649756 Thu, 24 Jul 2008 04:00:00 +0100 1649756 http://www.medworm.com/index.php?rid=1609326&cid=s_37711_13_f&fid=37711&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1753-5174.2008.00007.x Conclusions. Systemic exposure to FBT was approximately dose proportional across the range 100 µg to 800 µg in healthy Japanese adults. Adverse events were mild or moderate. (Source: Archives of Drug Information) Archives of Drug Information journals http://www.medworm.com/rss/comments.php?id=1609326 Fri, 11 Jul 2008 04:00:00 +0100 1609326 http://www.medworm.com/index.php?rid=1609329&cid=s_37711_13_f&fid=37711&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1753-5174.2008.00010.x Conclusion. In an open-label, observational study, desloratadine 5 mg once daily significantly decreased symptoms of chronic idiopathic urticaria and improved subject QoL. (Source: Archives of Drug Information) Archives of Drug Information journals http://www.medworm.com/rss/comments.php?id=1609329 Tue, 08 Jul 2008 04:00:00 +0100 1609329 http://www.medworm.com/index.php?rid=1609328&cid=s_37711_13_f&fid=37711&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1753-5174.2008.00009.x Conclusions. Bioavailability of fentanyl after FBT 400 µg administered as a single tablet was bioequivalent to that after 2 simultaneously administered 200 µg tablets in healthy Japanese volunteers. AEs were mild or moderate. (Source: Archives of Drug Information) Archives of Drug Information journals http://www.medworm.com/rss/comments.php?id=1609328 Sat, 28 Jun 2008 04:00:00 +0100 1609328 http://www.medworm.com/index.php?rid=1609327&cid=s_37711_13_f&fid=37711&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1753-5174.2008.00008.x Conclusions. Following administration of FBT at 6-hour intervals to healthy Japanese volunteers, at steady state, fentanyl exposure was higher by 55% (AUC0[ndash]6) and 23% (Cmax) than after a single dose of FBT. Adverse events were mild or moderate. (Source: Archives of Drug Information) Archives of Drug Information journals http://www.medworm.com/rss/comments.php?id=1609327 Sat, 28 Jun 2008 04:00:00 +0100 1609327